Regulation - Jetrea

Filter

Current filters:

Jetrea

Popular Filters

Thrombogenics gets Spanish reimbursement approval for Jetrea

Thrombogenics gets Spanish reimbursement approval for Jetrea

01-09-2014

Ophthalmic specialist ThromboGenics has received reimbursement in Spain from the Spanish Ministry of…

AlconJetreaNon-steroidal anti-inflammatory drugsOphthalmicsPharmaceuticalRegulationSpainThromboGenics

Thrombogenics’ Jetrea gains first Latin American approval in Uruguay

Thrombogenics’ Jetrea gains first Latin American approval in Uruguay

02-07-2014

Belgium-based biopharma firm ThromboGenics has said that Jetrea (ocriplasmin) has been approved in Uruguay…

JetreaOphthalmicsPharmaceuticalRegulationThromboGenicsUruguay

First Asian approval for ophthalmic drug Jetrea, in Malaysia

18-04-2014

Belgian biotech firm ThromboGenics NV revealed today that Jetrea (ocriplasmin) has been approved in Malaysia…

AlconAsia-PacificBiotechnologyJetreaMalaysiaNovartisOphthalmicsRegulationThromboGenics

Alcon and ThromboGenics launch Jetrea in Canada

21-11-2013

ThromboGenics NV (Euronext Brussels: THR) and its partner Alcon, the ophthalmic unit of Novartis (NOVN:…

AlconBiotechnologyCanadaJetreaMarkets & MarketingOphthalmicsRegulationThromboGenics

NICE issues final guidance on Jetrea

NICE issues final guidance on Jetrea

23-10-2013

NICE has published final guidance recommending Jetrea (ocriplasmin) from ThromboGenics.

EuropeJetreaOphthalmicsPharmaceuticalRegulationThromboGenics

Germany’s G-BA confirms benefits of ThromboGenics’ Jetrea for VMT

18-10-2013

Belgian biotech firm ThromboGenics says that the Final Early Benefit Assessment from the German Federal…

AlconBiotechnologyEuropeJetreaNovartisOphthalmicsPricingRegulationThromboGenics

Germany's IQWiG confirms Jetrea's added value for VMT patients

02-08-2013

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) announced today (August 2) that the…

BiotechnologyEuropeJetreaOphthalmicsPharmaceuticalPricingRegulationThromboGenics

ThromboGenics' Jetrea gets initial NICE recommendation for VMT

12-06-2013

Belgium-based biopharma company ThromboGenics (Euronext Brussels: THR) said this morning (June 12) that…

AlconEuropeJetreaNovartisOphthalmicsPharmaceuticalPricingRegulationThromboGenics

EU approval of Jetrea triggers a 45 million-euro milestone for ThromboGenics from Alcon

18-03-2013

The European Commission has approved Swiss drug major Novartis' (NOVN: VX) Alcon ophthalmic unit's Jetrea…

AlconEuropeFinancialJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

US FDA approves ThromboGenics' Jetrea; advisory backing for Aegerion's lomitapide

19-10-2012

Belgian drugmaker ThromboGenics NV (Euronext Brussels: THR) yesterday received US Food and Drug Administration…

Aegerion PharmaceuticalsCardio-vascularJetrealomitapideNorth AmericaOphthalmicsPharmaceuticalRegulationThromboGenics

COMPANY SPOTLIGHT

Menarini

Back to top